Safety and Efficacy of Upadacitinib Monotherapy in Adolescents and Adults with Moderate-to-severe Atopic Dermatitis: Results From 2 Pivotal, Phase 3, Randomized, Double-blinded, Monotherapy, Placebo-controlled Studies (Measure Up 1 and Measure Up 2)
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Acknowledgements
This is a highlights summary of an oral session given at the EADV Virtual Congress and presented by:
Emma Guttman-Yassky, MD, PhD
Ichan School of Medicine at Mount Sinai
New York, USA
The content is produced by Infomedica, the official reporting partner of EADV Virtual Congress. The summary text was drafted by Synthesis Editorial Ltd, and reviewed by Martina Lambertini, MD, an independent external expert, and approved by Prof. Brigitte Dréno, the scientific editor of the program.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
References
1. Parmentier JM, Voss J, Graff C, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol 2018;2:1–11.
2. Virtanen AT, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. BioDrugs 2019;33:15–32.
3. Cornelissen C, Lüscher-Firzlaff J, Baron JM, Lüscher B. Signaling by IL-31 and functional consequences. Eur J Cell Bio 2012:552–66.
4. Castro F, Cardoso AP, Gonçalves RM, et al. Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion. Front Immunol 2018:9:847.
5. Keegan AD, Zamorano J, Keselman A, Heller NM. IL-4 and IL-13 Receptor Signaling From 4PS to Insulin Receptor Substrate 2: There and Back Again, a Historical View. Front Immunol 2018:9:1037.
6. Nadier A, Stodtmann S, Friedel A, et al. Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials. J Clin Pharmacol 2020;60:528–39.
